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For more than two decades, immunologists have been using the so-called Th1/Th2 paradigm to explain most of 
the phenomena related to adaptive immunity. The Th1/Th2 paradigm implied the existence of two different, mutu-
ally regulated, CD4+ T helper subsets: Th1 cells, driving cell-mediated immune responses involved in tissue damage 
and fighting infection against intracellular parasites; and Th2 cells that mediate IgE production and are particu-
larly involved in eosinophilic inflammation, allergy and clearance of helminthic infections. A third member of the T 
helper set, IL-17-producing CD4+ T cells, now called Th17 cells, was recently described as a distinct lineage that does 
not share developmental pathways with either Th1 or Th2 cells. The Th17 subset has been linked to autoimmune 
disorders, being able to produce IL-17, IL-17F and IL-21 among other inflammatory cytokines. Interestingly, it has 
been reported that there is not only a cross-regulation among Th1, Th2 and Th17 effector cells but there is also a di-
chotomy in the generation of Th17 and T regulatory cells. Therefore, Treg and Th17 effector cells arise in a mutually 
exclusive fashion, depending on whether they are activated in the presence of TGF-β or TGF-β plus inflammatory 
cytokines such as IL-6. This review will address the discovery of the Th17 cells, and recent progress on their develop-
ment and regulation.
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Basis for the Th1/Th2 paradigm
An efficient adaptive immune response against patho-
gen antigen determinants is fundamental for their elimi-
nation by the host. At the same time, it is also crucial for 
host homeostasis that the immune system is able to toler-
ate self-components, as well as many foreign antigens, 
such as those from commensal bacteria and food. Uncov-
ering the mechanisms that enable the adaptive immune 
system to accomplish these tasks has always (and still is) 
been a big challenge. That was exactly the challenge mo-
tivating Christopher Parish’s research when he drew the 
basis for the later establishment of the Th1/Th2 paradigm.
Parish was employing antigen modification by ac-
etoacetylation to induce tolerance. He found that ac-
etoacetylated derivatives of flagellin (from Salmonella 
adelaide) were able to dramatically reduce a primary 
antigen response to unmodified flagellin in rats [1]. 
Unexpectedly, the same antigen modification led to an 
increased delayed-type hypersensitivity (DTH) response 
[2]. Thus, there was an inverse relationship between 
antigen response and DTH [3]. Although the term ‘im-
mune deviation’ had been coined a little earlier, that was 
the first strong evidence showing that humoral- and cell-
mediated immune responses could be cross-regulated 
[3]. One important question still remained: Are the T 
cells mediating DTH different from those helping B cells 
to produce antibodies? Although Parish and Liew per-
formed experiments suggesting the existence of different 
T-cell populations orchestrating humoral- and cell-medi-
ated responses [3, 4], a formal proof was still missing. It 
is important to keep in mind that at that time there were 
no monoclonal antibodies to surface markers and cytok-
ines. Actually, the discovery of cytokines was about 10 
years away and even distinguishing CD4 and CD8 cells 
was not as easy as it is today.
The Th1/Th2 paradigm
In the mid-1980s, the development of new techniques, 
such as the ability to clone T cells, and the MTT assay, 
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a colorimetric assay for cell growth, allowed this ques-
tion to be revisited (Figure 1). By combining these two 
new tools, Tim Mossman’s lab was able to distinguish 
two different types of T cells producing different growth 
factors. While Th1 cells would mainly produce IL-2 and 
IFN-γ, Th2 cells would produce a weaker T-cell growth 
factor distinct from IL-2 [5, 6]. At the same time, Bob 
Coffman’s lab had established a very sensitive and spe-
cific solid-phase assay for IgE, aiming at understanding 
how IgE production is regulated [5]. The two lines of re-
search came along very nicely when they decided to test 
supernatants from the two different T cell types in their 
assay for IgE production. Surprisingly, supernatants from 
a Th2 clone added to LPS-stimulated B cells led to robust 
IgE responses, whereas supernatants containing IL-2 and 
IFN-γ from Th1 clones induced no IgE production [5, 7]. 
Importantly, when both supernatants were added together 
no IgE was detected, demonstrating the ability of a Th1 
factor to block the Th2-induced IgE response. By using 
neutralizing antibodies (the only monoclonal antibody to 
a cytokine they had available at that time), they demon-
strated that the Th1 factor responsible for inhibiting Th2-
induced IgE production was IFN-γ [5, 7]. It was also 
found that the weaker T-cell growth factor released by 
Th2 clones that could induce IgE responses was actually 
IL-4, called B-cell stimulatory factor-1 (BSF-1) at that 
time [5, 8]. One year later, the last piece to build up the 
concept came when it was demonstrated that Th1 clones, 
but not Th2 clones, could mediate DTH responses [9].
The Th1/Th2 paradigm implies the existence of two 
different CD4+ T helper subsets. One of them, Th1, 
drives cell-mediated immune responses involved in tis-
sue damage and fighting infection against intracellular 
parasites and also provides help for B cells to produce 
certain isotypes of G immunoglobulin (Ig), specifically 
IgG2a [5, 10]. The other one, Th2, mediates IgE production 
and is largely involved in eosinophilic inflammation, allergy 
and clearance of helminthic infections [5, 10]. The concept 
also involved the notion that the two subsets are cross-
regulated. Thus, cytokines released from cells of one subset 
had the ability to stimulate its own subset in an autocrine 
fashion and, at the same time, inhibit the other subset.
The studies on the Th1/Th2 paradigm rapidly evolved 
to understand better what determines the differentiation 
of each subset and also the transcription factors involved 
in their regulation. Accumulating evidence shows that 
IL-12 is crucial for Th1-cell differentiation through Stat4 
(signal transducer and activator of transcription 4) and 
the activation of a unique transcription factor named T-bet 
(T-box expressed in T cells), which upregulates IFN-γ 
and downregulates IL-4 and IL-5 expression [11-13]. In 
contrast, IL-4 induces Th2-cell differentiation through 
Stat6 and activation of GATA3, which upregulates IL-4 
and IL-5, but downregulates IFN-γ expression [11, 13].
The Th1/Th2 paradigm proposed by Mosmann and 
Coffman had a profound impact on the way immunolo-
gists perceived adaptive immune responses and the recip-
rocal relationships that might exist among T-cell subsets 
(Figure 1). It has also helped our better understanding 
of factors that regulate atopic diseases as well as host 
resistance and susceptibility to intracellular pathogens 
such as Leishmania major [14]. Following the “fall” of 
suppressor T cells [15], it was also proposed to explain 
peripheral tolerance to self-components [16].
Contradictions of the Th1/Th2 paradigm
The Th1/Th2 paradigm was not sufficient to explain 
Figure 1 Timeline: advances on T helper research. Figure depicts some of the most relevant findings in the field of T helper 
research (based on the article written by FY Liew [133]).
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a lot of experimental evidence coming particularly from 
studies on autoimmune diseases. Following the concept 
that Th1 cells play a major role in tissue damage, one 
would predict that administration of IFN-γ (the main ef-
fector cytokine produced by Th1 cells) would worsen 
autoimmune diseases and, conversely, that blocking 
IFN-γ by either using neutralizing antibodies or delet-
ing IFN-γ gene would ameliorate autoimmune diseases. 
Those predictions could not be confirmed and experi-
mental data suggested just the opposite. In an animal 
model for multiple sclerosis, the experimental autoim-
mune encephalomyelitis (EAE), administration of IFN-γ 
reduced disease severity in susceptible strains of mice 
and rats [17-19]. Accordingly, treatment with neutral-
izing antibodies to IFN-γ rendered EAE-resistant strains 
susceptible to a very severe form of the disease [17, 20]. 
In a similar way, disruption of the gene encoding ei-
ther IFN-γ or IFN-γ receptor converted otherwise EAE-
resistant strains to a susceptible phenotype, suggesting a 
protective role for IFN-γ in EAE [21, 22]. In the BALB/c 
strain, IFN-γ disruption was associated with an enhanced 
T-cell response to MBP [22]. Moreover, animals lacking 
other molecules involved in Th1 differentiation, such as 
Stat1 and the IL-12 receptor β2, were also shown to be 
not only susceptible but to develop more severe disease 
[23, 24]. Altogether, these data challenged the concept 
that Th1 cells play an essential role in pathogenesis of 
autoimmune diseases.
Contradictory data supporting the Th1 relevance in 
EAE came from studies utilizing T-bet-deficient mice 
and transfer of myelin antigen-specific Th1 cells to na-
ïve recipient animals. Deletion of the gene encoding the 
transcription factor T-bet was shown to confer resistance 
to EAE in mice immunized with MOG peptide [23]. Ac-
cordingly, it has been reported that upon transfer to naïve 
animals, activated Th1 cells are able to induce EAE in 
mice and rats [25, 26]. In addition, studies using IL-12 
p40 gene-targeted animals and neutralizing antibodies to 
IL-12 p40 suggested that IL-12, the main inductor of Th1 
responses, was necessary for EAE development [27, 28]. 
In summary, although experimental evidence suggested 
a role for Th1 cells in autoimmune diseases, it also dem-
onstrated that Th1 cells alone could not fully explain 
autoimmune disease pathogenesis, thus implying that an 
important piece of the puzzle was missing.
Discovering IL-23 and Th17 cells
The discovery of IL-23 [29], a new member of the 
IL-12 cytokine family started to shed some light on the 
scene and clarify why autoimmune diseases could not be 
completely explained by the Th1/Th2 paradigm (Figure 
1). IL-12 is a heterodimeric molecule formed by sub-
units p35 and p40. IL-23 is also a heterodimeric cytokine 
composed by the same subunit p40 but now paired with 
the unique p19 [29, 30]. IL-23, like IL-12, is mainly 
produced by cells of the innate immune system, such as 
dendritic cells (DCs) and tissue-resident macrophages. 
However, while some microbial products preferentially 
induce IL-12 expression, DC activation with PGE2, ATP 
or anti-CD40 antibodies elicits production of IL-23 [30-
32]. Cua et al. [33] dissected the participation of IL-12 
and IL-23 in EAE induction by using animals with gene 
disruption for each of the subunits forming IL-12 and IL-
23: p19, p35 and p40. They were able to show that ani-
mals deficient in IL-23 (p19−/−) and in both IL-12 and IL-
23 (p40−/−) were protected from EAE. In contrast, mice 
deficient only in IL-12 (p35−/−) were highly susceptible to 
EAE induction [33]. Moreover, IL-23 gene transfer vec-
tors delivered into the CNS reconstituted EAE in both 
p19−/− and p40−/− mice. Finally, IL-12 gene transfer into 
the CNS did not facilitate disease in p40−/− animals [33]. 
Thus, IL-23 rather than IL-12 is a crucial cytokine for 
the development of CNS autoimmune inflammation.
Besides being part of the same cytokine family and 
sharing the subunit p40, IL-23 and IL-12 also signal 
through similar receptors. IL-12 signals through a recep-
tor complex composed of IL-12Rβ1 and IL-12Rβ2 [30]. 
IL-23 in turn signals through a heterodimeric receptor 
made of the sharing IL-12Rβ1 subunit plus a unique IL-
23R subunit [30]. Since the two cytokines and their re-
ceptors are closely related, it was first predicted that IL-
12 and IL-23 would exert similar functions. So, at first, 
it was proposed that IL-12 and IL-23 could play comple-
mentary roles, with IL-23 being essential to mediate or 
sustain late-stage chronic inflammation [33]. However, 
soon data appeared demonstrating that was not the case 
and that actually, IL-12 and IL-23 were responsible for 
driving different T-cell subsets (see below).
Daniel Cua’s group extended their findings using 
a different animal model for autoimmune disease, the 
collagen-induced arthritis. Again using gene-targeted 
mice lacking only IL-12 (p35−/−) or IL-23 (p19−/−), they 
showed that the specific absence of IL-23 is protective, 
whereas the loss of IL-12 exacerbates collagen-induced 
arthritis [34]. IL-23 gene-targeted mice did not develop 
clinical signs of disease and were completely resistant to 
the development of joint and bone pathology [34]. Re-
sistance correlated with the absence of IL-17-producing 
CD4+ T cells despite normal induction of collagen-specif-
ic, interferon-γ-producing Th1 cells. In contrast, IL-12-
deficient p35−/− mice developed more IL-17-producing 
CD4+ T cells [34].
In fact, Aggarwal et al. [35] had demonstrated earlier 
Th17 cells
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that activation of CD4+ T cells in the presence of IL-23 
leads to elevated IL-17 production, a phenotype dis-
tinct from those described previously by Mosmann and 
Coffman (Figure 1). In contrast, the main Th1 inductor 
cytokine IL-12 induced only marginal IL-17 production 
[35]. That was further confirmed and extended by Cua 
and colleagues [36]. They have shown that in contrast 
to IL-12, IL-23 does not promote the development of 
interferon-γ-producing Th1 cells, but is one of the es-
sential factors required for the expansion of a distinct 
pathogenic CD4+ T-cell population, which is character-
ized by the production of IL-17, IL-17F, IL-6 and tumor 
necrosis factor [36]. Gene expression analysis of IL-23-
driven autoreactive T cells identified a unique expression 
pattern of proinflammatory cytokines and other novel 
factors, distinguishing them from IL-12-driven T cells. 
Using passive transfer studies, it was demonstrated that 
these IL-23-dependent CD4+ T cells are highly pathogen-
ic and essential for the establishment of organ-specific 
inflammation associated with central nervous system au-
toimmunity [36]. These findings were extended and IL-
17-producing CD4+ T cells were shown to play a funda-
mental role in different models of autoimmune diseases. 
Indeed, IL-17-deficient mice have reduced collagen-
induced arthritis [37] and, when immunized with myelin 
antigens in CFA, develop EAE with delayed onset and 
diminished severity [38]. Consistently, treatment with an 
IL-17R antagonist attenuated adjuvant-induced arthritis 
in rats [39] and administration of blocking antibodies to 
IL-17 prevented chemokine expression in the brain and 
subsequent EAE development in mice [40].
In addition to their role in the development of auto-
immune diseases, IL-17-producing CD4+ T cells were 
also shown to constitute an important arm of adaptive 
immune responses conferring protection against extracel-
lular pathogens [41]. It was reported that in vitro T-cell 
activation in the presence of conditioned media from 
Klebsiella pneumoniae-pulsed dendritic cells led to IL-
17 production in an IL-23-dependent manner [42]. In 
addition, similar to IL-12 p35−/− animals, IL-23 p19-
deficient mice are more susceptible to lung infection with 
Klebsiella pneumoniae [42]. Increased mortality in p19−/− 
animals was associated with dramatically reduced IL-17 
production in the lungs and administration of exogenous 
IL-17 was able to restore bacterial control [42]. Con-
sistently, IL-17R-deficient animals were reported to be 
exquisitely sensitive to intranasal Klebsiella pneumoniae 
with 100% mortality 48 h after infection [43]. The role 
played by IL-17-producing T cells in controlling certain 
extracellular pathogens may be of particular relevance 
in infections associated with immunodeficient condi-
tions such as AIDS. In fact, it was recently demonstrated 
that in simian immunodeficiency virus (SIV)-infected 
rhesus macaques, T cell-driven IL-17 responses against 
Salmonella typhimurium were markedly blunted, which 
led to increased bacterial dissemination [44]. In the same 
context, IL-17-producing cells are also known to play an 
important role in the establishment of effective immune 
responses to Mycobacterium tuberculosis mainly through 
the recruitment of protective IFN-γ-producing CD4+ T 
cells [45].
Then, besides Th1 and Th2, the third member of the 
effector T-cell trilogy, Th17, arises [46] (Figure 1). Two 
independent groups proposed that IL-17-producing CD4+ 
T cells, so-called Th17, are a distinct lineage that does 
not share developmental pathways with either Th1 or 
Th2 cells [47, 48]. Hence, it was demonstrated that Th17 
differentiation does not require any of the transcription 
factors involved in Th1 (such as T-bet, Stat4 and Stat1) 
or Th2 (such as Stat6 and c-Maf) development [47, 48]. 
Moreover, IL-17 expression was increased substantially 
when anti-IFN-γ and anti-IL-4 were added during T-cell 
differentiation, suggesting that IFN-γ and IL-4 negatively 
regulate the generation of IL-17-producing cells [47, 48]. 
Thus, it was proposed that in the absence of IFN-γ and 
IL-4, IL-23 induces naïve precursor cells to differentiate 
into Th17 cells [47]. However, it had been already shown 
that unlike memory cells, naïve T cells do not express the 
receptor for IL-23 [35]. Thus, it was unlikely that IL-23 
would be the dominant factor required for Th17 differen-
tiation. Indeed, independent studies demonstrated that a 
combination of the pro-inflammatory cytokine IL-6 and 
TGF-β could induce in vitro differentiation of truly naïve 
T cells into IL-17-producing cells [49, 50, 134].
The importance of this combination of cytokines for 
the development of Th17 cells in vivo was also docu-
mented. Upon ex vivo stimulation with antigen, CD4+ T 
cells from mice bearing a transgenic TCR recognizing 
MOG and expressing TGF-β under the IL-2 promoter re-
lease high concentrations of TGF-β and can protect naïve 
recipients from EAE [51]. However, upon in vivo immu-
nization with MOG in CFA, which leads to elevated IL-6 
production by the innate immune system, those animals 
developed more severe EAE associated with increased 
IL-17 production by T cells [49]. Another important 
piece of data pointing to the importance of TGF-β signal-
ing on induction of Th17 cells came from experiments 
utilizing CD4-DNTGFBRII mice. These animals, which 
express a dominant-negative mutant of TGF-β receptor 
II in CD4 cells, are deficient in Th17 cells and are more 
resistant to EAE [52]. The crucial participation of TGF-β 
in promoting differentiation of Th17 cells was surprising 
since TGF-β has long been recognized as an important 
molecule regulating adaptive immune responses [53] 
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and, particularly, as being directly responsible for de 
novo generation of peripheral Foxp3+ regulatory T cells 
(iTreg) [54-57]. Altogether, the important concept of re-
ciprocal developmental pathways for the generation of 
pathogenic effector Th17 and regulatory T cells [49] had 
been established. It seems that there is not only a func-
tional antagonism between Th17 and T regulatory (Treg) 
cells but that there is a dichotomy in their generation as 
well. Therefore, Treg cells and Th17 effectors arise in a 
mutually exclusive manner, depending on whether they 
are activated in the presence of TGF-β or TGF-β plus 
IL-6 [49].
At the steady-state level or in the absence of any in-
flammatory insult, TGF-β produced in the immune sys-
tem has the capacity to suppress the generation of effec-
tor T cells and induce Foxp3+ regulatory T cells, thereby 
contributing to the maintenance of homeostasis. This 
pathway has particular relevance at mucosal surfaces 
such as the intestine, where both intense microbial load 
and production of TGF-β are constant under physiologi-
cal conditions. In this regard, intestinal tissue has been 
shown to be highly effective at inducing iTregs (induc-
ible Tregs). Lafaille’s group, for instance, has shown by 
using mice lacking nTregs (natural Tregs) that iTregs are 
sufficient for oral tolerance induction [58, 59]. Belkaid 
and Powrie’s groups confirmed and extended these find-
ings by demonstrating that iTregs were preferentially 
induced in mesenteric LN (MLN) and lamina propria 
by a subpopulation of DCs, rather than in the spleen or 
peripheral lymph nodes, reinforcing that the intestine is 
a privileged site for Treg induction [60, 61]. Importantly, 
the intestinal cells also produce a “co-factor” for Treg 
development, the vitamin-A metabolite retinoic acid (RA) 
(discussed below) [60-63].
At the same time, the intestine also harbors high 
amounts of IL-17-producing T cells at steady state, 
which correlates with the fact that inflammatory cytok-
ines are produced physiologically in the intestine [64-
66]. Therefore, upon infection or inflammation, IL-6 
produced by the activated innate immune system is able 
to suppress the generation of TGF-β-induced Treg cells 
and induce a pro-inflammatory T-cell response predomi-
nated by Th17 cells [49]. In a recent study, Ivanov et 
al. [66] reported that commensal bacteria are required 
for IL-17 production in the small intestine, since germ-
free mice contained virtually no Th17 cells in the lamina 
propria. Moreover, upon introduction of bacteria from 
SPF mice (conventionalization), these formerly germ-
free animals induced IL-17 production in the lamina pro-
pria. Surprisingly, neither Trif nor Myd88 were required 
for this “spontaneous” IL-17 production in the lamina 
propria, indicating that toll-like receptor signaling was 
not involved in this phenomenon [66]. An explanation 
for these findings could be found in the recent report 
by Atarashi et al. [67], who have shown that adenosine 
5′-triphosphate (ATP) derived from commensal bacteria 
can activate a subset of lamina propria cells (CD70high-
CD11clow cells) that are able to produce IL-6, IL-23 and 
TGF-β, triggering the differentiation of Th17 cells. A 
balance between these pro-inflammatory and anti-inflam-
matory functions of TGF-β is crucial to maintain im-
mune tolerance to self or to the non-pathogenic non-self 
(microbiota and food antigens) and, at the same time, to 
keep an immune-tonus that generates efficient adaptive 
immune response against antigen determinants derived 
from pathogens.
Following the suggestion that IL-6 plays a pivotal role 
in dictating whether precursor cells in the presence of 
TGF-β will become either Treg or Th17 effector cells, 
one would predict that animals deficient in IL-6 do not 
mount efficient Th17 responses. IL-6-deficient mice had 
already been described as resistant to EAE induction, 
although the reasons for this were not clear [68, 69]. 
Consistent with the concept of reciprocal development 
of Treg and Th17 cells, upon immunization with MOG, 
IL-6-deficient mice fail to generate a Th17 response and 
present increased numbers of T regulatory cells in the 
peripheral repertoire [70]. These findings raised the ques-
tion of whether the increased numbers of Tregs in IL-6-
deficient animals are an important factor in protecting 
them from EAE. In fact, depletion of Tregs with an anti-
CD25 antibody prior to MOG immunization rendered IL-
6-deficient mice susceptible to EAE [70]. Surprisingly, 
however, there was a re-appearance of Th17 cells that 
could be isolated from the target organ in these animals 
[70], suggesting that there is an alternate pathway re-
sponsible for the generation of Th17 effector cells in the 
absence of IL-6. Two independent groups have shown 
that this alternate factor involved in Th17 generation is 
IL-21 [70, 71]. Thus, in the absence of IL-6, IL-21 to-
gether with TGF-β was shown to inhibit development of 
iTregs and to promote the differentiation of Th17 cells 
[70]. Moreover, IL-21-deficient animals are more resis-
tant to EAE and even in the presence of IL-6 and TGF-β 
their naïve CD4 T cells poorly differentiate into Th17 
[71]. Consistent with this, IL-21 receptor-deficient mice 
also generate decreased Th17 responses [70].
Although IL-23 is not involved in the initial steps 
driving the differentiation of naïve T cells into IL-17-
producing cells, it plays a fundamental role in stabilizing 
the phenotypic features of the Th17 lineage. Without IL-
23, T cells reactivated in the presence of only IL-6 plus 
TGF-β can produce high amounts of IL-17, but can not 
fully develop into pathogenic cells and acquire bystander 
Th17 cells
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regulatory properties mediated by IL-10 production [72]. 
Thus, IL-23 is essential for Th17 cells to fully differenti-
ate and exhibit effector function. Indeed, antigen-specific 
CD4+ T cells activated in the presence of TGF-β and 
IL-6 not only are unable to induce disease upon transfer 
but they can protect mice from EAE when co-transferred 
with fully differentiated pathogenic Th17 cells driven by 
IL-23 [72]. These findings suggest that proliferation (in 
vitro and in vivo) and IL-17 production by T cells do not 
always correlate with their ability to induce inflammation 
and tissue damage. The difference in the ability of T cells 
activated in the presence of either IL-6 plus TGF-β or 
IL-23 to induce disease rather correlated with expression 
of chemokines such as IP-10, CCL2, CCL5, CCL22 and 
CXCL2 [72]. Moreover, these findings suggest that the 
same combination of cytokines driving initial commit-
ment of the Th17 lineage may initiate a regulatory loop 
in which activated Th17 cells, by producing IL-10, con-
strain its own effector function. A similar self-regulatory 
circuit was also described for effector Th1 cells during 
infection with intracellular parasites such as Leishmania 
major and Toxoplasma gondii [73, 74]. During the course 
of the infection, under strong inflammatory conditions, 
IFN-γ-secreting T-bet+ Foxp3− T helper type 1 (Th1) cells 
were found to be the major producers of IL-10 and para-
doxically, displayed potent effector function against the 
parasite while also inducing profound suppression of IL-
12 production by antigen-presenting cells [74].
Transcriptional control of the Th17 program
As mentioned above, the fact that Th17 cells can 
develop independently of transcription factors, such 
as Stat1, Stat4, Stat6, T-bet and c-Maf, indicated that 
they represent a distinct lineage of effector cells [47, 
48]. Studies using two independent approaches led to 
the discovery of the RA-related orphan receptor (ROR)
gammat as the key transcription factor for generation of 
Th17 cells. One involved comparison of gene expression 
profiles of activated T cells stimulated with IL-23 (Th17) 
and Th1 cells. While Th1 cells greatly expressed T-bet, 
in Th17 cells rorcgamma, the gene encoding RORγt, 
appeared as the best candidate among sequences for 
DNA-binding proteins [30, 75, 76]. The other approach 
involved mice expressing green fluorescent protein (GFP) 
along with expression of RORγt. Analysis of the GFP+ 
cells in this mouse strain revealed that those were the 
cells expressing IL-17 [75, 76]. These findings estab-
lished a clear association between RORγt and IL-17 ex-
pression. Further experiments using RORγt-deficient ani-
mals showed that expression of RORγt is both necessary 
and sufficient to drive the differentiation of Th17 cells 
[64]. CD4+ T cells from RORγt-deficient animals are un-
responsive to IL-23 upon stimulation in vitro and poorly 
differentiate into IL-17-producing cells [64]. Further-
more, forced expression of RORγt in naïve CD4+ T cells 
was sufficient to induce expression of IL-17, IL-17F and 
IL-22. Finally, RORγt-deficient animals are resistant to 
EAE induction [64]. Recently, it was demonstrated that 
RORα synergizes with RORγt to promote differentiation 
of Th17 cells [77].
Although RORγt is crucial, other transcription factors, 
such as Stat3, are also required for full generation of the 
Th17 lineage [75, 78, 79]. The most recent model pro-
poses that TGF-β and IL-6 initially drive the expression 
of IL-21 in a Stat3-dependent manner [75]. It was dem-
onstrated that IL-21 expression induced by IL-6 depends 
on Stat3, but not on RORγt [75, 80]. IL-21 then starts 
a positive loop in which it induces its own expression 
and also the expression of RORγt and of IL-23 receptor. 
Accordingly, IL-23R expression is greatly reduced in 
IL-21R-deficient animals [75, 80]. IL-21-induced self-
expression is only dependent on Stat3, while induction 
of the IL-23 receptor requires both Stat3 and RORγt [75, 
80]. IL-23 induces further expression of its own receptor 
and of RORγt. Thus, IL-21, by inducing its own expres-
sion and RORγt expression, and IL-23, by driving ex-
pression of its own receptor and further inducing RORγt 
expression, are thought to represent two important loops 
expanding and stabilizing cells of the Th17 lineage [75, 
80]. Interestingly, it was found that upon activation of na-
ïve T cells IL-6 and IL-21 alone are able to drive IL-23R 
and some RORγt expression, but without TGF-β they are 
unable to induce high IL-17 and IL-17F production [71]. 
A number of studies have also proposed that Th17 induc-
tion in human cells was independent of TGF-β [81-83]. 
However, as it has been shown by Littman, Soumelis and 
Hafler’s groups, these conclusions were jeopardized by 
two main drawbacks: contaminant TGF-β in the human 
serum and incomplete isolation of truly pure naïve CD4+ 
T cells [84-86]. The signals downstream to TGF-β recep-
tor cooperating with IL-6 and IL-21 to induce high levels 
of IL-17 in T cells remain to be elucidated.
The transcription factor aryl hydrocarbon receptor 
(AHR) was also recently shown to be a regulator of Th17 
and Treg-cell differentiation. AHR is a ligand-dependent 
transcription factor with a promiscuous ligand-binding 
site, wherein structurally diverse synthetic and naturally 
occurring ligands have been identified [87]. Among 
these are halogenated aromatic hydrocarbons, non-
halogenated polycyclic aromatic hydrocarbons such as 
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), and also 
natural ligands such as the tryptophan photoproduct, 
6-formylindolo[3,2-b]carbazole (FICZ) [87]. AHR seems 
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to play opposite roles in Th17 and Treg-cell differentia-
tion in a ligand-dependent fashion. Thus, while TCDD 
favored the development of Tregs and can protect mice 
from EAE [88], FICZ was shown to increase Th17 re-
sponses and to induce stronger EAE in mice [88, 89]. 
AHR has been reported to interact with different tran-
scription partners depending on the ligand or on the acti-
vation pathway [90-92]. For instance, AHR is known to 
associate and regulate the activity of transcription factors 
such as the RA receptor [93] and the estrogen receptor 
[94], two receptors that influence Treg and Th17 differ-
entiation [62, 95].
Interferon-regulatory factor 4 (IRF4) was also shown 
to play an important role in the differentiation of Th17 
cells. IRF4-deficient animals are resistant to EAE and 
transfer of wild-type T helper cells into IRF4-deficient 
recipients rendered them susceptible to the disease [96]. 
In addition, T cells from IRF4-deficient mice failed to 
differentiate into IL-17-producing cells in vitro. Upon 
activation in the presence of TGF-β and IL-6, IRF4-
deficient T cells did not downregulate Foxp3 expression 
and low levels of RORγt were detected [96]. Forced 
expression of RORγt partially rescued their ability to be 
converted into Th17. The authors concluded that the de-
fective Th17 differentiation of Irf4−/− T helper cells could 
be partially attributed to a lack of IL-6-mediated down-
regulation of Foxp3 [96]. Indeed, it was recently found 
that Foxp3 inhibits Th17 differentiation, at least in part, 
by direct interaction with RORγt [97-99], which also 
helps to explain the reciprocal development of T regula-
tory and Th17 cells. Actually, RORγt and Foxp3 may 
coexist in the same cell [65, 98]. It was reported that, in 
vivo, an important fraction of RORγt T cells is comprised 
by cells with regulatory properties which also express 
Foxp3 and produce CCL20 and IL-10 [65]. In influenza 
A-virus-infected lungs, the amount of RORγt-expressing 
cells increased by more than 10-fold; however, the pro-
portion between IL-17- and IL-10-producing (Foxp3+) 
RORγt cells remained constant [65]. The authors pro-
posed the existence of a robust mechanism maintaining 
the equilibrium between Th17 and Tregs within RORγt 
cells during infection [65]. Keeping the balance of IL-17 
versus IL-10 production would promote inflammation, 
while limiting collateral damage, a necessary compro-
mise between effective immunity and tissue integrity. 
Factors such as IL-6 and IL-23 twist the balance favor-
ing Th17 responses, as the ratio of IL-17-producing to 
Foxp3+ RORγt T cells decreased in IL-6- or IL-12Rβ1-
deficient mice [65]. Conversely, Foxp3 and CCL20 skew 
the balance to the other side, favoring the Treg arm, as 
inferred by the increased ratio of Th17 to Tregs in scurfy 
and CCR6-deficient mice [65].
Negative regulators of Th17 development
The first cytokines described to negatively regulate 
Th17 generation were IFN-γ (Th1) and IL-4 (Th2). In 
fact, blocking antibodies to IFN-γ and IL-4 facilitate 
in vitro differentiation of IL-17-producing T cells [47, 
48]. Accordingly, IFN-γ-deficient mice developed more 
severe antigen-induced arthritis associated with unre-
stricted IL-17 response [100]. Moreover, forced expres-
sion of T-bet, an important Th1 transcription factor, in 
naïve CD4 T cells blocked IL-17 production under Th17 
polarizing conditions [75]. Similarly, T cells from mice 
overexpressing c-Maf, a Th2 transcription factor impor-
tant for IL-4 expression, showed much less IFN-γ and 
IL-17 production upon activation [48]. Altogether, the 
data suggest some cross-regulation among Th1, Th2 and 
Th17 subsets.
IL-2 also emphasizes the reciprocal development of T 
regulatory and Th17 cells. IL-2 has been reported as es-
sential for TGF-β conversion of naïve CD4+ T cells into 
Foxp3+ T regulatory cells [101, 102]. Moreover, IL-2 
together with TGF-β seems to be important to stabilize 
phenotypic features of inducible Tregs by downregulat-
ing IL-6R expression and rendering them resistant to 
further Th17 conversion by IL-6 [103]. In vivo, IL-2 sig-
naling also seems to be critically required for maintain-
ing the homeostasis and competitive fitness of naturally 
occurring Treg cells [104]. In contrast, IL-2 signaling 
via Stat5 was shown to constrain Th17 generation upon 
activation of naïve T cells in the presence of IL-6 and 
TGF-β [105]. Stat5-dependent IL-2-mediated inhibition 
of Th17 differentiation seems to require Ets-1. Thus, Ets-
1-deficient T cells presented increased resistance to the 
inhibitory effect of IL-2 on Th17 differentiation and this 
was associated with a defect downstream of Stat5 phos-
phorylation [106]. IL-2 deficiency was also shown to be 
associated with increased Th17 generation in vivo [105]. 
Interestingly, addition of IL-2 to T cell cultures in the 
presence of TGF-β and IL-6 was able to not only block 
conversion of naïve T cells into Th17 cells, but also 
drive generation of Treg cells [105]. Foxp3+ T regulatory 
cells are thus thought to be great consumers of IL-2 and 
restricting IL-2 availability may be one means by which 
they can constrain Th1 and Th2 cells [107]. Following 
the same rationale, by restricting IL-2 availability, T 
regulatory cells could instead fuel the generation of Th17 
cells. However, experimental evidence for this is still 
lacking.
In a similar way, RA produced by intestinal DCs has 
been shown to favor Foxp3+ T regulatory cell genera-
tion and to constrain Th17 conversion [62] (reviewed 
in [108]). RA signaling through RAR receptors in the 
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T cells is able to block the inhibitory effects of inflam-
matory cytokines, such as IL-6, on the TGF-β-mediated 
Foxp3 induction, while efficiently suppressing primary 
and secondary development of IL-17-producing CD4 and 
CD8 T cells [62, 109]. Additionally, it was shown that 
RA directly inhibits TGF-β and IL-6-induced expression 
of RORγt in T cells [62, 110]. Additional mechanisms for 
this dual function of RA in T-cell differentiation were re-
cently proposed by Xiao and coworkers. They suggested 
that RA can enhance TGF-β signaling by increasing the 
expression and phosphorylation of Smad3, and inhibit 
the expression of IL-6Rα and IL-23R [111], therefore 
simultaneously increasing the ability of TGF-β to induce 
Foxp3 and suppressing Th17 differentiation.
RA nuclear receptors RARs have been shown to 
form heterodimers with STATs, and particularly STAT5 
and RARs can physically interact in vivo to promote 
RAR-mediated transcription [112], indicating that RA-
mediated effects on Treg and Th17 differentiation could 
reflect this communication between STAT5 and RAR. 
Mucida et al. found that IL-2 signaling could play a role 
in the reciprocal regulation of Th17 and Treg differen-
tiation mediated by RA, since both the enhancement of 
Foxp3 expression and suppression of IL-17 production 
were drastically reduced in the presence of high amounts 
of anti-IL-2 blocking antibodies or when IL-2-deficient 
naïve CD4 T cells were used. However, the direct ef-
fects of RA and IL-2 appear distinct: while the combina-
tion of IL-2 and TGF-β induced mostly CD103−Foxp3+ 
Treg cells, RA and TGF-β induced preferentially 
CD103+Foxp3+ cells [62]. Using similar in vitro ap-
proaches, Elias et al. [110] suggested that neither STAT3 
nor STAT5 is required for the RA-mediated regulation. 
The authors found that in STAT3 or STAT5 conditional 
knockout CD4 T cells, RA still mediates enhancement of 
Foxp3 expression and suppression of IL-17 production, 
respectively. It is possible that the high dose of RA used 
in this study (1 µM) [110] could bypass the requirement 
for IL-2 [62], since depending on the dose of ligands, the 
balance between co-repressors (CoRs) and co-activators 
(CoAs) can alter the function of nuclear receptor ligands 
and therefore change their signaling cascade and the ef-
fects on the target genes [113, 114].
The dose of RA was also suggested to play a role in 
the suppression of Th17 differentiation. In contrast to 
previous studies, Uematsu et al. [115] have recently sug-
gested that a low dose of RA promotes differentiation 
of antigen-specific Th17 and Th1 cells. This conclusion 
was based on experiments showing that the addition of 
RAR antagonist, LE540, inhibited an already modest 
IL-17 production [115]. The authors suggested that the 
discrepancy between this result and previously published 
data [62, 109, 110, 116] was due to the dose of RA, 
since addition of an extremely high dose of RA (10 µM) 
inhibited IL-17 production by CD4+ T cells. However, 
previous studies that described the suppressive effects 
of RA on Th17 development performed dose-response 
experiments in which RA suppressed IL-17 responses in 
all doses examined, starting from 1 nM (the same used 
by Uematsu) to 100 nM [62] and 10 µM [110]. A typical 
dose-response curve of Th17 suppression by RA was also 
observed by Kattah and coworkers using a range from 
1 nM to 1 µM in human cells [116]. More importantly, 
spontaneous production of RA by mucosal DCs in T/DC 
co-cultures also inhibited IL17 production and enhanced 
Foxp3 induction, while addition of RAR antagonist in 
these cultures reversed this effect [60-62], which indi-
cates that “physiological production” of RA by gut-de-
rived DCs would be enough to suppress, but not induce, 
IL-17 production, and enhance TGF-β-mediated Foxp3 
induction. It is possible, however, that under certain con-
ditions such as under TLR stimulation, RA might have 
dual effects on DCs and T cells. For example, simultane-
ous exposure of TLR ligands such as pIC and LPS led to 
synergistic effects on IL-6 production [117].
IL-27, another member of the IL-12 cytokine family, 
has been demonstrated to be a negative regulator of Th17 
responses. IL-27 is a heterodimeric cytokine made of 
Epstein-Barr virus-induced gene 3 (EBI3) and p28 chains 
[30]. IL-27 signals through a receptor composed of the 
IL-27 receptor chain (also called WSX-1 or TCCR) and 
the gp130 chain, which is shared with the IL-6 receptor 
[30]. IL-27R-deficient animals are more susceptible to 
EAE and this is associated with higher IL-17 production 
by lymph node T cells upon ex vivo stimulation and more 
intense CNS infiltration by Th17 cells [118]. IL-27 via 
Stat1 was also found to prevent in vitro differentiation of 
Th17 cells [118, 119]. Consistently, CD4+ T cells from 
EBI3-deficient mice produced higher levels of IL-17, IL-
22, and RORγt upon stimulation under Th17 polarizing 
conditions [120]. Although IL-27 has been shown to 
favor T-bet expression and Th1 differentiation via Stat1 
[121, 122], its effect on preventing Th17 generation was 
independent of T-bet and IFN-γ [118]. These findings 
suggest it is unlikely that IL-27 suppresses Th17 devel-
opment by simply diverting naïve T cells into Th1, but 
rather it may do so by directly interfering with RORγt 
expression. Alternatively, in vivo IL-27 may also con-
strain Th17 responses by inducing IL-10-producing T 
cells [123-125]. It was already shown that modified IL-
27-producing DCs drive the generation of IL-10-produc-
ing T cells [123].
Th17 responses were also reported to be constrained 
by Trif-dependent type I IFN production and its down-
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stream signaling pathway. Mice with defects in Trif or 
type I IFN receptor (IFNAR) developed more severe 
EAE [126]. Notably, these mice exhibited marked CNS 
inflammation, as manifested by increased IL-17 produc-
tion [126]. In addition, IFNAR-dependent signaling 
events were essential for negatively regulating Th17 de-
velopment. Finally, IFN-β-mediated IL-27 production by 
innate immune cells was critical for the immunoregula-
tory role of IFN-β in the CNS autoimmune disease [126].
IL-25 (IL-17E), a member of the IL-17 cytokine fam-
ily, was also demonstrated to be an important regulator 
of Th17 responses. IL-25-deficient mice are highly sus-
ceptible to EAE, which is associated with an increase of 
IL-23 in the periphery and increased numbers of inflam-
matory IL-17- and TNF-producing T cells that invade 
the central nervous system [127]. Consistently, treatment 
with recombinant IL-25 or IL-25 delivered by a viral 
vector system was effective in suppressing EAE in wild-
type animals. IL-25 treatment induced elevated produc-
tion of IL-13, which was required for suppression of 
Th17 responses by direct inhibition of IL-23, IL-1β and 
IL-6 expression in activated DCs [127]. In accordance 
with the observed IL-25-mediated IL-13 production, IL-
25 is thought to be an important inducer of Th2 respons-
es [128, 129].
Concluding remarks
Fine-tuning and tight control of ongoing adaptive im-
mune responses are crucial for host immune homeosta-
sis. A functional immune system is supposed to provide 
efficient protection against invading pathogens and trans-
formed autologous cells and, at the same time, to tolerate 
self-components and non-hazardous non-self antigens. 
Although the Th1/Th2 paradigm represented a strong 
experimental and theoretical basis allowing significant 
advances in the immunology field, it was proven insuffi-
cient to fully explain certain immunological phenomena. 
Aberrant immune responses directed towards harmless 
non-self agents or normal endogenous cells can lead to 
severe autoimmune disorders, and just central deletion of 
auto-reactive T cells could not satisfactorily explain self-
tolerance [130, 131]. Indeed, self-reactive Foxp3+ regula-
tory T cells were also shown to be indispensable for pre-
venting excessive and self-destructive immune responses 
[132]. The description of the Th17 subset also had an im-
mediate impact in the way we depict autoimmune diseas-
es and inflammatory T helper cells. The fact that the Treg 
and Th17 cells have reciprocal developmental pathways 
and, at the same time, opposite roles in the generation 
and control of inflammation provides a new framework 
that is certainly contributing to our comprehension of 
the adaptive immune system functioning. However, we 
should not expect that adding two new T-cell subsets will 
give us a complete picture and rather a lot more layers 
of complexity will be necessary to uncover the ways the 
adaptive immune system swings between tolerance and 
effector responses.
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